Novartis Sickle-Cell Drug Gets US Approval

The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.

from NDTV Profit - Latest https://ift.tt/2NQv31m